eFFECTOR Therapeutics, Inc.
EFTR
$0.0002
$0.000.00%
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 675.00K | 1.54M | 3.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 675.00K | 1.54M | 3.55M |
| Cost of Revenue | 21.62M | 22.92M | 23.50M | 24.77M | 26.81M |
| Gross Profit | -21.62M | -22.92M | -22.82M | -23.23M | -23.26M |
| SG&A Expenses | 11.09M | 10.93M | 11.15M | 12.14M | 12.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.70M | 33.84M | 34.64M | 36.91M | 38.94M |
| Operating Income | -32.70M | -33.84M | -33.97M | -35.37M | -35.39M |
| Income Before Tax | -34.63M | -35.81M | -35.94M | -37.20M | -35.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.63 | -35.81 | -35.94 | -37.20 | -35.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.63M | -35.81M | -35.94M | -37.20M | -35.75M |
| EBIT | -32.70M | -33.84M | -33.97M | -35.37M | -35.39M |
| EBITDA | -32.59M | -33.73M | -33.86M | -35.27M | -35.32M |
| EPS Basic | -13.32 | -17.11 | -19.26 | -21.71 | -21.54 |
| Normalized Basic EPS | -8.32 | -10.70 | -12.04 | -13.60 | -13.98 |
| EPS Diluted | -13.32 | -17.11 | -19.26 | -21.71 | -21.58 |
| Normalized Diluted EPS | -8.32 | -10.70 | -12.04 | -13.60 | -13.98 |
| Average Basic Shares Outstanding | 11.14M | 8.73M | 7.73M | 6.90M | 6.63M |
| Average Diluted Shares Outstanding | 11.14M | 8.73M | 7.73M | 6.90M | 6.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |